International Journal of PharmTech Research
CODEN (USA): IJPRIF, ISSN: 0974-4304, ISSN(Online): 2455-9563
Vol.12, No.02, pp 139-144, 2019

Enteric dispersion of Serratiopeptidase with Eudragit L100 and Formulation of Controlled Release Tablets of Serratiopeptidase

A Prameela Rani and Annapurna Uppala*

University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Nagarjuna Nagar – 522510, India

Abstract: Serratiopeptidase is an anti inflammatory enzyme commonly used in the treatment of various inflammatory disorders. It is found to have no GI related side effects unlike NSAIDs and can be safely used for chronic conditions. Formulations of controlled release tablets can decrease the frequency of administration and thereby improve the patient compliance. As Serratiopeptidase is acid-liable, it is made into enteric dispersion with the polymer viz. Eudragit L 100 by solvent evaporation technique. The polymer is used in various proportions and the optimum solid dispersion was selected based on the drug release study for enteric products. The controlled release tablets of the Serratiopeptidase solid dispersion were prepared with the polymers viz. ethyl cellulose, hydroxypropylmethylcellulose and methylcellulose in various proportions. Drug release study was conducted for 6 hours in pH 6.8 phosphate buffer. The formulation containing ethyl cellulose in 125 mg quantity showed drug release in controlled manner upto 6 hours.

Key words: Enteric dispersion, Serratiopeptidase, Eudragit L100, Controlled Release Tablets.

Annapurna Uppala *et al* /International Journal of PharmTech Research, 2019,12(2): 139-144.

DOI: http://dx.doi.org/10.20902/IJPTR.2019.120207

***** *****